Frontiers in Immunology (Dec 2024)
Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults
- Kohei Kometani,
- Takaaki Yorimitsu,
- Takaaki Yorimitsu,
- Norihide Jo,
- Norihide Jo,
- Erina Yamaguchi,
- Osamu Kikuchi,
- Osamu Kikuchi,
- Osamu Kikuchi,
- Masaru Fukahori,
- Masaru Fukahori,
- Takeshi Sawada,
- Takeshi Sawada,
- Yoshitaka Tsujimoto,
- Yoshitaka Tsujimoto,
- Ayana Sunami,
- Ayana Sunami,
- Mengqian Li,
- Takeshi Ito,
- Yann Pretemer,
- Yuxian Gao,
- Yuxian Gao,
- Yu Hidaka,
- Masaki Yamamoto,
- Natsuko Kaku,
- Natsuko Kaku,
- Yu Nakagama,
- Yu Nakagama,
- Yasutoshi Kido,
- Yasutoshi Kido,
- Alba Grifoni,
- Alessandro Sette,
- Alessandro Sette,
- Miki Nagao,
- Satoshi Morita,
- Takako E. Nakajima,
- Takako E. Nakajima,
- Manabu Muto,
- Manabu Muto,
- Manabu Muto,
- Yoko Hamazaki,
- Yoko Hamazaki,
- Yoko Hamazaki
Affiliations
- Kohei Kometani
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Takaaki Yorimitsu
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Takaaki Yorimitsu
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Norihide Jo
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Norihide Jo
- Alliance Laboratory for Advanced Medical Research, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Erina Yamaguchi
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Osamu Kikuchi
- Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Osamu Kikuchi
- Clinical Bio-Resource Center, Kyoto University Hospital, Kyoto, Japan
- Osamu Kikuchi
- Center for Cancer Immunotherapy and Immunobiology, Kyoto University, Kyoto, Japan
- Masaru Fukahori
- Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Masaru Fukahori
- Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan
- Takeshi Sawada
- Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Takeshi Sawada
- Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan
- Yoshitaka Tsujimoto
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yoshitaka Tsujimoto
- Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Ayana Sunami
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Ayana Sunami
- 0Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Mengqian Li
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Takeshi Ito
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yann Pretemer
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yuxian Gao
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yuxian Gao
- 0Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Yu Hidaka
- 1Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Masaki Yamamoto
- 2Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Natsuko Kaku
- 3Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
- Natsuko Kaku
- 4Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Yu Nakagama
- 3Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
- Yu Nakagama
- 4Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Yasutoshi Kido
- 3Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
- Yasutoshi Kido
- 4Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
- Alba Grifoni
- 5Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States
- Alessandro Sette
- 5Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States
- Alessandro Sette
- 6Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, United States
- Miki Nagao
- 2Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Satoshi Morita
- 1Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Takako E. Nakajima
- Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Takako E. Nakajima
- Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan
- Manabu Muto
- Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Manabu Muto
- Clinical Bio-Resource Center, Kyoto University Hospital, Kyoto, Japan
- Manabu Muto
- Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, Kyoto, Japan
- Yoko Hamazaki
- Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Yoko Hamazaki
- 0Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- Yoko Hamazaki
- 7Kyoto University Immunomonitoring Center, Kyoto, Japan
- DOI
- https://doi.org/10.3389/fimmu.2024.1455334
- Journal volume & issue
-
Vol. 15
Abstract
Age-associated differences in the effect of repetitive vaccination, particularly on memory T-cell and B-cell responses, remain unclear. While older adults (aged ≥65 years) exhibited enhanced IgG responses following COVID-19 mRNA booster vaccination, they produced fewer spike-specific circulating follicular helper T cells-1 than younger adults. Similarly, the cytotoxic CD8+ T-cell response remained diminished with reduced PD-1 expression even after booster vaccination compared with that in younger adults, suggesting impaired memory T-cell activation in older adults. In contrast, although B-cell responses in older adults were weaker than those in younger adults in the primary response, the responses were significantly enhanced upon booster vaccination, reaching levels comparable with that observed in younger adults. Therefore, while booster vaccination ameliorates impaired humoral immunity in older adults by efficiently stimulating memory B-cell responses, it may less effectively enhance T-cell-mediated cellular immunity. Our study provides insights for the development of effective therapeutic and vaccine strategies for the most vulnerable older population.
Keywords
